NCE-1 Intelligence & Market Opportunity

Truseltiq

Infigratinib

Anticancer

Oral Capsule

Approval Date

28-May-21

NCE-1 Date

28-May-25

NCE Date

28-May-26

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

197

2029

372

2030

566

2031

754

2032

909

Molecule profile

Details & specifications

Molecule

Infigratinib

Innovator

HELSINN HLTHCARE

Dosage Form

Oral Capsule

Strength

25 mg, 100 mg

Therapeutic Category

Anticancer

Usage

To treat cholangiocarcinoma whose disease meets certain criteria

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.